Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone

Completed · Not applicable

Conditions studied: Major Depressive Disorder

In brief

Major depressive disorder (MDD) is highly prevalent and nearly 70% of individuals with MDD do not respond to standard antidepressant therapies despite adequate dosing. An effective and well-tolerated antidepressant augmentation therapy would have important clinical and public health implications. Neuroactive steroid hormones are known to directly activate neurotransmitter receptors in the brain, and thus are potential candidates for augmentation therapies to enhance the effect of traditional antidepressants. The investigators hypothesize that administration of an allopregnanolone analog in women with treatment-resistant depression will improve depressive symptoms.

Key facts

Study ID

NCT02900092

Run by

Massachusetts General Hospital

People needed

10

Starts

2016-11-01

Expected to finish

2018-01-12

Last updated by the study team

2019-02-18

Who can join

Age: 50 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female, age 50-75
• Postmenopausal
• Major Depressive Disorder
• Currently treated with SSRI or SNRI at adequate dose

You may not qualify if…

• Serious suicide or homicide risk
• Unstable medical illness
• Substance use disorder
• Psychosis
• Use of hormones (estrogens, androgens or related hormones)
• History of hormone responsive cancer
• Receiving strong CYP3A4 inducers or inhibitors or who intend to consume grapefruit products regularly during the study
• Alanine aminotransferase (ALT) or creatinine > 3x upper limit of normal

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.